
Sign up to save your podcasts
Or


For the full presentation, downloadable slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/TQX865. CME/MOC/NCPD/AAPA credit will be available until January 27, 2026.
A Recap of Therapeutic Advances in HER2-Positive, HER2-Low, and HER2-Ultralow Breast Cancer: Navigating the Latest Evidence and Maximizing Clinical Impact
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Disclosure information is available at the beginning of the video presentation.
By PVI, PeerView Institute for Medical Education4.1
2525 ratings
For the full presentation, downloadable slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/TQX865. CME/MOC/NCPD/AAPA credit will be available until January 27, 2026.
A Recap of Therapeutic Advances in HER2-Positive, HER2-Low, and HER2-Ultralow Breast Cancer: Navigating the Latest Evidence and Maximizing Clinical Impact
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Disclosure information is available at the beginning of the video presentation.

43,643 Listeners

137 Listeners

319 Listeners

702 Listeners

500 Listeners

28 Listeners

10 Listeners

1,382 Listeners

5 Listeners

10 Listeners

4 Listeners

2 Listeners

4 Listeners

2 Listeners

3 Listeners

5 Listeners

5 Listeners

2 Listeners

0 Listeners

9 Listeners

2 Listeners

12 Listeners

2 Listeners

4 Listeners

3 Listeners

5 Listeners

289 Listeners

263 Listeners

3,341 Listeners

1,150 Listeners

191 Listeners

88 Listeners

514 Listeners

368 Listeners

431 Listeners